Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

• Chunyan Gu,
• Yajun Wang,
• Lulin Zhang,
• Li Qiao,
• Shanliang Sun,
• Miaomiao Shao,
• Xiaozhu Tang,
• Pinggang Ding,
• Chao Tang,
• Yuhao Cao,
• Yanyan Zhou,
• Mengjie Guo,
• Rongfang Wei,
• Nianguang Li,
• Yibei Xiao,
• Jinao Duan,
• Ye Yang

Affiliations

Chunyan Gu

Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine

Yajun Wang

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Lulin Zhang

School of Pharmacy, Nanjing University of Chinese Medicine

Li Qiao

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Shanliang Sun

School of Pharmacy, Nanjing University of Chinese Medicine

Miaomiao Shao

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Xiaozhu Tang

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Pinggang Ding

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Chao Tang

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Yuhao Cao

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Yanyan Zhou

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Mengjie Guo

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Rongfang Wei

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine

Nianguang Li

School of Pharmacy, Nanjing University of Chinese Medicine

Yibei Xiao

School of Pharmacy, China Pharmaceutical University

Jinao Duan

School of Pharmacy, Nanjing University of Chinese Medicine

Ye Yang

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine